E. Hilger
Medical University of Vienna
36 Papers
266 Citations
E. Hilger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Medicine & Reboxetine. The author has an hindex of 19, co-authored 35 publications. Previous affiliations of E. Hilger include University of Vienna.
Chat about Author
Papers
Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls.
Alexander Neumeister,Matthäus Willeit,Nicole Praschak-Rieder,Susanne Asenbaum,J. Stastny,E. Hilger,Walter Pirker,Anastasios Konstantinidis,Siegfried Kasper +8 more
TL;DR: These data suggest reductions in the availability of striatal DAT binding sites in untreated symptomatic depressed SAD patients, providing evidence that brain dopaminergic systems may be involved in the pathophysiology of SAD.
118
Affective state of women following a prenatal diagnosis: predictors of a negative psychological outcome.
Katharina Leithner,A. Maar,Melitta Fischer-Kern,E. Hilger,Henriette Löffler-Stastka,Elisabeth Ponocny-Seliger +5 more
TL;DR: The main aim of the present study was to investigate the potential relationship between psychological outcome and associated variables in women attending a tertiary referral center for prenatal diagnosis and therapy for ultrasound scanning, amniocentesis or chorionic villus sampling.
106
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
TL;DR: Reboxetine was significantly superior to the serotonergic compound fluoxetine in improvement of social functioning in both the general depressed population and in those patients who achieved symptomatic remission, indicating a superior quality of remission.
58
Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder
Nicole Praschak-Rieder,Matthäus Willeit,Alexander Neumeister,E. Hilger,J. Stastny,N. Thierry,Elisabeth Lenzinger,Siegfried Kasper +7 more
TL;DR: Preliminary evidence for a high point prevalence rate of PMDD in premenopausal females with SAD is provided, and an additional diagnosis of PM DD has an impact on the clinical outcome and the response to bright light therapy in female patients with S AD.
55
Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder.
Nicole Praschak-Rieder,Matthäus Willeit,Dietmar Winkler,Alexander Neumeister,E. Hilger,Peter Zill,Kurt Hornik,J. Stastny,N. Thierry,Manfred Ackenheil,Brigitta Bondy,Siegfried Kasper +11 more
TL;DR: The elevated rate of affective disorders in relatives of patients with SAD and PMDD suggests higher genetic vulnerability in this subgroup when compared to patients withSAD alone.
49